Using ΔAUC, drug classes with enriched activity against hereditary diffuse gastric cancer c.1380delA CDH1 SB.mhdgc-1 cells include mTOR, MEK, FAK, ROCK, and protein kinase C inhibitors, with aurora kinase inhibitors showing a trend towards greater activity, whereas bromodomain-containing protein 4 (BRD4), phospho-diesterase (PDE5A) inhibitors, and to a lesser degree, HDAC and HER receptor inhibitors showed preferentially greater activity in the sporadic wild type CDH1 SB.msgc-1 cells. The gene discussed is MAP2K7; the disease is Familial gastric cancer.